Morgan Stanley upgraded Evotec to Equal Weight from Underweight with a price target of $12, up from $11. The analyst cites the resent in consensus estimates for the upgrade. Consensus EBITDA estimates now reflect the Evotec’s investment in Just Bio, meaning the downgrade cycle should have largely played out, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVO:
